Autolus Therapeutics plc (AUTL) Institutional Ownership & Insider Trading

84 institutions reported holding Autolus Therapeutics plc shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 1 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

AUTLAutolus Therapeutics plcFollow AUTL — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 409.9M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 10 Nov, in 17 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

84 institutions held 49.7% of the shares. Across filers that reported both quarters, shares held changed -1.7%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	84	132	-1.7%	25	8	21	9
Mar 26	84	134	-4.0%	22	9	28	11
Dec 25	89	139	-2.3%	24	9	29	18
Sep 25	93	144	-13.1%	32	13	21	11
Jun 25	93	166	-1.2%	30	19	25	19
Mar 25	93	168	-0.2%	28	9	31	22
Dec 24	106	168	-4.5%	32	18	29	13
Sep 24	97	178	-1.2%	28	5	34	16

Autolus Therapeutics plc — questions

Who owns Autolus Therapeutics plc stock?: 84 institutions reported Autolus Therapeutics plc shares in 13F filings for the quarter ended 2026-06-30. The largest: MAK CAPITAL ONE LLC (12.6%), Blackstone Inc. (7.7%), Syncona Portfolio Ltd (6.3%).
Are Autolus Therapeutics plc insiders buying or selling?: 1 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Autolus Therapeutics plc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.